Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | hexokinase | 0.0802 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0248 | 0.2546 | 0.2546 |
Brugia malayi | hexokinase type II | 0.0255 | 0.2638 | 0.2638 |
Loa Loa (eye worm) | hypothetical protein | 0.0255 | 0.2638 | 0.2638 |
Plasmodium vivax | hexokinase, putative | 0.0802 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.0802 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0503 | 0.5978 | 0.5978 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0204 | 0.1945 | 0.1945 |
Toxoplasma gondii | hexokinase | 0.0802 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 1 | 0.0802 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.0248 | 0.2546 | 0.2546 |
Trypanosoma cruzi | hexokinase, putative | 0.0802 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0177 | 0.1584 | 0.1584 |
Echinococcus multilocularis | hexokinase type 2 | 0.0802 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.0802 | 1 | 1 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0204 | 0.1945 | 0.1945 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0204 | 0.1945 | 0.1945 |
Echinococcus granulosus | hexokinase type 2 | 0.0802 | 1 | 1 |
Onchocerca volvulus | 0.0802 | 1 | 1 | |
Leishmania major | hexokinase, putative | 0.0802 | 1 | 0.5 |
Plasmodium falciparum | hexokinase | 0.0802 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0802 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.0802 | 1 | 1 |
Treponema pallidum | hexokinase (hxk) | 0.0802 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.0802 | 1 | 0.5 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.019 | 0.1765 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0222 | 0.2197 | 0.2197 |
Echinococcus multilocularis | hexokinase | 0.0802 | 1 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0222 | 0.2197 | 0.2197 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.019 | 0.1765 | 0.5 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0204 | 0.1945 | 0.1945 |
Brugia malayi | Hexokinase family protein | 0.0802 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0802 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.0802 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0547 | 0.6568 | 0.6568 |
Onchocerca volvulus | 0.0802 | 1 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0255 | 0.2638 | 0.2638 |
Schistosoma mansoni | hexokinase | 0.0802 | 1 | 1 |
Leishmania major | hexokinase, putative | 0.0802 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0802 | 1 | 1 |
Onchocerca volvulus | 0.0802 | 1 | 1 | |
Brugia malayi | Hexokinase family protein | 0.0503 | 0.5978 | 0.5978 |
Echinococcus granulosus | hexokinase | 0.0802 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.0802 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.0802 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.0802 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | 0.0024 uM | ST_JUDE: Cytotoxicity using Alamar Blue to measure viability of Leishmania major | ChEMBL. | 20485428 |
EC50 (functional) | 0.3211 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum SB-A6 | ChEMBL. | 20485428 |
EC50 (functional) | 0.626 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum 3D7 | ChEMBL. | 20485428 |
EC50 (functional) | 0.6443 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum Dd2 | ChEMBL. | 20485428 |
EC50 (functional) | 0.7815 uM | ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye | ChEMBL. | 20485428 |
EC50 (functional) | 0.8683 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum D10 transfected with yeast DHOD | ChEMBL. | 20485428 |
EC50 (functional) | 0.9015 uM | ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye | ChEMBL. | 20485428 |
EC50 (functional) | 0.962 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum K1 | ChEMBL. | 20485428 |
EC50 (functional) | 2.5841 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum V1/S | ChEMBL. | 20485428 |
EC50 (functional) | 3.5388 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum W2 | ChEMBL. | 20485428 |
EC50 | 6.783 uM | ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human epithelial hepatocellular carcinoma cells (HepG2) | ChEMBL. | 20485428 |
EC50 (functional) | 7.886 uM | ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of Trypanosoma brucei | ChEMBL. | 20485428 |
EC50 | 13.7075 uM | ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human Burkitt''s lymphoma lymphoblast cells (Raji) | ChEMBL. | 20485428 |
EC50 | 15.2105 uM | ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human foreskin fibroblast cells (BJ) | ChEMBL. | 20485428 |
EC50 | 16.7681 uM | ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human epithelial embryonic kidney cells (HEK293) | ChEMBL. | 20485428 |
EC50 (functional) | > 22.336 uM | ST_JUDE: Growth inhibition of to Toxoplasma gondii, in human U-2OS cells, as measured by luciferase. | ChEMBL. | 20485428 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Leishmania major | ChEMBL23 | 20485428 | |
Trypanosoma brucei | ChEMBL23 | 20485428 | |
Trypanosoma brucei gambiense | 20485428 | ||
Homo sapiens | ChEMBL23 | 20485428 | |
Plasmodium falciparum | ChEMBL23 | 20485428 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.